An Ag and Health Microbiome startup, the initial effort by Oakgrove Bio management is to develop a recombinant technology platform with the objective being to decrease cost of manufacturing of peptides beyond what is currently commercially feasible. With the firm's principal experienced in the field, the approach is to address peptide production from a different perspective than that of current recombinant peptide production technologies. Specifically, the approachis to take advantage of the fact that peptides can be treated as polymers rather than as folded proteins with a complex structure, novel microbial cell factories will enable the peptide production and purification.
